Targeting a specific enzyme to improve mitochondrial function in Parkinson's disease
USP30 Inhibition as a Therapeutic Strategy in Parkinson's Disease
This study is looking at how a specific enzyme called USP30 can help clean up damaged parts of cells in the brain, which is important for people with Parkinson's disease, and it hopes to find new ways to protect against the harmful effects of a protein linked to the condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10809860 on NIH RePORTER |
What this research studies
This research investigates the role of USP30, a deubiquitinating enzyme, in enhancing the process of mitophagy, which is crucial for maintaining healthy mitochondria in the brain. By focusing on the dysfunction of mitochondrial homeostasis linked to Parkinson's disease, the study aims to understand how improving mitophagy can protect against the toxic effects of α-synuclein, a protein associated with the disease. The approach involves examining the interactions between mitochondrial proteins and the mechanisms that lead to the degradation of dysfunctional mitochondria. Patients may benefit from insights that could lead to new therapeutic strategies for managing Parkinson's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease, particularly those with autosomal recessive forms linked to Parkin deficiency.
Not a fit: Patients with Parkinson's disease who do not have mitochondrial dysfunction or those with other unrelated neurological disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve mitochondrial function and slow the progression of Parkinson's disease.
How similar studies have performed: Previous research has shown promising results in targeting mitochondrial dysfunction in neurodegenerative diseases, suggesting that this approach may yield significant advancements.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Simon, David K. — Beth Israel Deaconess Medical Center
- Study coordinator: Simon, David K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.